drugset / Trial / NCT05624723
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center, open-label, parallel-group study to evaluate oral doses of INCB054707 in participants with varying levels of renal function or impairment.
Timeline
- Start
- 2023-01-12
- Primary completion
- 2024-02-07
- Completion
- 2024-02-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Povorcitinib | Small molecule | 75 mg | Oral |